HTG Molecular to Present a Corporate Overview at the Cantor Fitzgerald Global Healthcare Conference
TUCSON, Ariz., Sept. 26, 2018 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a provider of instruments, reagents, and services for molecular profiling applications, today announced that TJ Johnson, Chief Executive Officer, will present a corporate overview at the Cantor Fitzgerald Global Healthcare Conference, being held October 1-2, 2018 at the InterContinental New York Barclay Hotel in New York City.
|
HTG Molecular Diagnostics Presentation Details | |
| Date: | Tuesday, October 2, 2018 |
| Time: | 2:15pm Eastern Time |
| Location: | InterContinental New York Barclay Hotel |
| Track 6 – Rockefeller Suite | |
About HTG:
HTG is focused on next generation sequencing (NGS) based molecular profiling. The company’s proprietary HTG EdgeSeq technology automates complex, highly multiplexed molecular profiling from solid and liquid samples, even when limited in amount. HTG’s customers use its technology to identify biomarkers important for precision medicine, to understand the clinical relevance of these discoveries, and ultimately to identify treatment options. Our mission is to empower precision medicine at the local level.
Contact:
Ashley R. Robinson
LifeSci Advisors, LLC
Phone: (617) 525-7754
Email: arr@lifesciadvisors.com
TJ Johnson
Chief Executive Officer
HTG Molecular Diagnostics
Email: tjjohnson@htgmolecular.com
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
